GF/B46/EDP06
Approved by the Board on: 22 December 2021
Extension of the COVID-19 Response Mechanism and COVID-19 Operational Flexibility
- Based on the rationale provided in GF/B46/ER06, the Board:
- Approves that any additional 6th Replenishment pledges received through 30 September 2022 will be used to support the COVID-19 Response Mechanism (C19RM);
- Approves that any additional C19RM funds may be awarded through 31 March 2023;
- Approves to revise the thresholds for Board approval of C19RM awards set out in paragraph 5.d of GF/B44/EDP18 based on the total additional C19RM funding made available, as follows:
- If up to US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 45 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 15 million, where such increases scale-up interventions approved by the Board;
- If more than US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 55 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 20 million, where such increases scale-up interventions approved by the Board; and
- Threshold amounts will continue to be measured in aggregate by country, not including any amounts awarded under the fast-track approach or C19RM funds awarded in 2020;
- Agrees that all other parameters of C19RM under GF/B44/EDP18 remain unchanged; and
- Approves that the Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 December 2023.
Budgetary Implications
Incremental management and operating costs directly attributable to C19RM will continue to be covered by up to 3% of any funds made available for C19RM.